FDA Approves Gemtuzumab Ozogamicin for CD33-Positive AML in Pediatric Patients
On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARGTM, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older.
On June 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA®, Merck & Co., Inc.) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Categories
- Blog Posts (30)
- Guest Blogs (6)
- Member Blogs (19)
- Survivorship Matters Blog (5)
- CAC2 News (5)
- Collaborative Achievements (12)
- Community News (43)
- Research Explained (4)
- Uncategorized (18)
- Webinars (53)